Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome‐associated febrile crisis

Summary Hyper‐IgD and periodic fever syndrome (HIDS) is a hereditary autoinflammatory syndrome, characterized by recurrent inflammatory attacks. Treatment of HIDS is difficult. Recently, the IL‐1ra analogue anakinra was reported to be successful in aborting the IgD inflammatory attacks in a vaccinat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of inherited metabolic disease 2006-12, Vol.29 (6), p.763-763
Main Authors: Cailliez, M., Garaix, F., Rousset‐Rouvière, C., Bruno, D., Kone‐Paut, I., Sarles, J., Chabrol, B., Tsimaratos, M.
Format: Article
Language:English
Subjects:
Fever - etiology
Fever - therapy
Humans
Hypergammaglobulinemia - complications
Hypergammaglobulinemia - therapy
Immunoglobulin D - chemistry
Inflammation
Interleukin 1 Receptor Antagonist Protein - therapeutic use
Syndrome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Hyper‐IgD and periodic fever syndrome (HIDS) is a hereditary autoinflammatory syndrome, characterized by recurrent inflammatory attacks. Treatment of HIDS is difficult. Recently, the IL‐1ra analogue anakinra was reported to be successful in aborting the IgD inflammatory attacks in a vaccination model. We report a clinical case of spectacular reduction of febrile attacks in a severe HIDS patient.
ISSN:0141-8955
1573-2665
DOI:10.1007/s10545-006-0408-7